drugset
drugset / Trial / NCT00004249

Vaccine Therapy Plus QS21 in Treating Patients With Small Cell Lung Cancer That Has Responded to Initial Therapy

NCT00004249 ↗

Phase 2 Completed Memorial Sloan Kettering Cancer Center National Cancer Institute (NCI) · collab
Treatment

Summary

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Biological therapies, such as QS21, use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy plus QS21 in treating patients who have small cell lung cancer that has responded to initial therapy.

Timeline

Start
1998-08
Primary completion
2001-11
Completion
2001-11

Drugs

EvaluationDrugModalityDoseRoute
Subject polysialic acid Unknown — Subcutaneous
Background QS-21 Other / unclassified — Subcutaneous
Background keyhole limpet hemocyanin Vaccine — Subcutaneous

Indications

small cell lung carcinoma